180 related articles for article (PubMed ID: 18671710)
1. Efficacy of the endothelin receptor blocker bosentan for refractory sickle cell leg ulcers.
Lionnet F; Bachmeyer C; Stankovic K; Tharaux PL; Girot R; Aractingi S
Br J Haematol; 2008 Sep; 142(6):991-2. PubMed ID: 18671710
[No Abstract] [Full Text] [Related]
2. Successful treatment with bosentan of non-digital skin ulcers in severe scleroderma.
Ferreira ME; Scheinberg MA
Ann Rheum Dis; 2008 Dec; 67(12):1784-5. PubMed ID: 19005155
[No Abstract] [Full Text] [Related]
3. Efficacy of Bosentan in treatment of refractory sclerodermic bone prominences skin ulcers.
Richetta AG; Mattozzi C; Maiani E; D'Epiro S; Cimillio M; Carboni V; Giancristoforo S; Calvieri S
Clin Ter; 2008; 159(5):317-9. PubMed ID: 18998033
[TBL] [Abstract][Full Text] [Related]
4. Bosentan as a rescue therapy in scleroderma refractory digital ulcers.
Chamaillard M; Heliot-Hosten I; Constans J; Taïeb A
Arch Dermatol; 2007 Jan; 143(1):125-6. PubMed ID: 17224564
[No Abstract] [Full Text] [Related]
5. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
[TBL] [Abstract][Full Text] [Related]
6. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
[TBL] [Abstract][Full Text] [Related]
7. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis.
Taniguchi T; Asano Y; Hatano M; Tamaki Z; Tomita M; Kawashima T; Miyazaki M; Sumida H; Akamata K; Takahashi T; Ichimura Y; Toyama T; Sugita M; Noda S; Yao A; Kinugawa K; Sato S
Br J Dermatol; 2012 Feb; 166(2):417-21. PubMed ID: 21848685
[TBL] [Abstract][Full Text] [Related]
8. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
[TBL] [Abstract][Full Text] [Related]
9. Bosentan: a novel therapy for leg ulcers in Werner syndrome.
Noda S; Asano Y; Masuda S; Miyagawa T; Sugita M; Yamamoto M; Kogure A; Tamaki Z; Mitsui H; Hoashi T; Sugaya M; Sato S
J Am Acad Dermatol; 2011 Aug; 65(2):e54-e55. PubMed ID: 21763553
[No Abstract] [Full Text] [Related]
10. [Endothelin receptor antagonist bosentan. Breakthrough in the treatment of pulmonary hypertension].
MMW Fortschr Med; 2004 Dec; 146(50):72-3. PubMed ID: 15666438
[No Abstract] [Full Text] [Related]
11. Bosentan for the treatment of adult pulmonary hypertension.
Dwyer N; Kilpatrick D
Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
[TBL] [Abstract][Full Text] [Related]
12. Topical GM-CSF hastens healing of leg ulcers in sickle cell disease.
Alikhan MA; Carter G; Mehta P
Am J Hematol; 2004 Jun; 76(2):192. PubMed ID: 15164391
[No Abstract] [Full Text] [Related]
13. [Bosentan].
Taéron C
Rev Infirm; 2005 Feb; (108):33-4. PubMed ID: 15816717
[No Abstract] [Full Text] [Related]
14. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan.
Nakwan N; Choksuchat D; Saksawad R; Thammachote P; Nakwan N
Acta Paediatr; 2009 Oct; 98(10):1683-5. PubMed ID: 19523174
[TBL] [Abstract][Full Text] [Related]
15. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
16. Bosentan for chronic thromboembolic pulmonary hypertension.
Confalonieri M; Kodric M; Longo C; Vassallo FG
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
[TBL] [Abstract][Full Text] [Related]
17. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
Sogni P; Moreau R; Gomola A; Gadano A; Cailmail S; Calmus Y; Clozel M; Lebrec D
Hepatology; 1998 Sep; 28(3):655-9. PubMed ID: 9731554
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and endothelin receptor antagonist in primary Sjögren's syndrome with pulmonary arterial hypertension.
Chen CH; Chen HA; Yang KY; Yu WC; Liao HT; Huang DF
Scand J Rheumatol; 2006; 35(3):245-7. PubMed ID: 16766376
[No Abstract] [Full Text] [Related]
19. Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy.
Tillon J; Hervé F; Chevallier D; Muir JF; Levesque H; Marie I
Br J Dermatol; 2006 May; 154(5):1000-2. PubMed ID: 16634913
[No Abstract] [Full Text] [Related]
20. [Bosentan for treatment of heart failure].
Yoshimoto T; Hirata Y
Nihon Rinsho; 2007 May; 65 Suppl 5():159-63. PubMed ID: 17571378
[No Abstract] [Full Text] [Related]
[Next] [New Search]
